N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME
about
B-type natriuretic peptide-guided treatment for heart failure.Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence.Fluid overload at start of continuous renal replacement therapy is associated with poorer clinical condition and outcome: a prospective observational study on the combined use of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretWhich heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)NT-proBNP: A Guide to Improve the Management of Patients with Heart Failure.Circulating biomarkers in patients with heart failure and preserved ejection fraction.Natriuretic peptide-guided heart failure management.Circular RNAs in heart failure.Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure.Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial.Prognostic impact of systemic inflammatory diseases in elderly patients with congestive heart failure.Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction.Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
P2860
Q30238936-20CDEB5B-3500-40C3-8A64-6D086AD35206Q35139977-55AFFE52-608B-4B4E-8EDA-94A5FE01F7C3Q35342135-810DA6B5-A826-48B0-BAF8-452BF7E225A3Q35792547-33EC433F-AF87-4B81-AA50-3E29FD5F04A7Q36985609-A0440578-A469-4306-B074-9759FDE0749DQ37155044-08B75E78-C718-4206-9B55-101F460DCCBDQ38152289-2C0567CB-7E9C-4C48-8E70-6AC4C50D4E31Q38161695-5483B54B-2774-4E28-8383-CD734AC70D1DQ38739402-D8E46884-926D-4B8D-B74D-2D71EE86DE25Q39127729-5538FCC1-7B57-4C11-8202-CEA46EAD9FACQ41165768-AB7F997B-EB5B-4D0D-A54E-17D433F6CDF6Q41239335-47379985-4325-4A4A-94F9-DF1E8E4E7BDCQ41250771-2ACB4E25-4258-43FC-B69C-B1B114980F1FQ45093738-84BAF62E-15A6-4825-8E1B-7234B299CC21Q48725493-13547302-90E6-498E-8F45-7F534B99D0A4Q48787655-45AEBC97-5250-4F5C-819A-C6FD7FF8E032Q50798879-46D64355-F4A3-40EA-9639-0F1CCC7BAC7D
P2860
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
N-terminal pro brain natriuret ...... congestive heart failure (TIME
@en
N-terminal pro brain natriuret ...... with congestive heart failure
@nl
type
label
N-terminal pro brain natriuret ...... congestive heart failure (TIME
@en
N-terminal pro brain natriuret ...... with congestive heart failure
@nl
prefLabel
N-terminal pro brain natriuret ...... congestive heart failure (TIME
@en
N-terminal pro brain natriuret ...... with congestive heart failure
@nl
P2093
P2860
P921
P356
P1476
N-terminal pro brain natriuret ...... congestive heart failure (TIME
@en
P2093
André Vuilliomenet
Hans Rickli
Heidi Abbühl
Marc Gutmann
Martin Peter
Matthias Pfisterer
Micha T Maeder
Peter Rickenbacher
TIME-CHF Investigators
P2860
P304
P356
10.1093/EURJHF/HFT076
P577
2013-05-08T00:00:00Z